Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2010

01-09-2010 | Preclinical study

Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice

Authors: Reginald M. Gorczynski, Zhiqi Chen, Jun Diao, Ismat Khatri, Karrie Wong, Kai Yu, Julia Behnke

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Login to get access

Abstract

CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in a number of human malignancies. We have found that cells of the transplantable EMT6 mouse breast cancer line growing in vitro express low levels of CD200, but levels increase markedly during growth in immunocompetent mice. Similar increased in vivo expression does not occur in NOD-SCID.IL-2γr−/− mice or mice with generalized over-expression of a CD200 transgene. In both mice, tumor growth occurs faster. Altered CD200 expression in control versus transgenic mice is accompanied by reproducible changes in tumor-infiltrating host cells, and altered cell composition in lymph nodes draining the tumor (DLN). Neutralization of expressed CD200 by anti-CD200mAbs leads to decreased tumor growth in immunocompetent mice, with improved detection of cytotoxic anti-tumor immune cells in DLN. Finally, we report that tumor growth in vivo can be monitored by levels of soluble CD200 (sCD200) in serum of tumor-bearing animals.
Literature
1.
Kato M, Slack FJ (2008) Micro RNAS: small molecules with big roles—C. elegans to human cancer. Biol Cell 100:71–81CrossRefPubMed
2.
Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, Schultz P, Warmuth M (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13:944–951CrossRefPubMed
3.
Salih HR, Kosowski SG, Haluska VF, Starling GC, Loo DT, Lee F, Aruffo AA, Trail PA, Kiener PA (2000) Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 165:2903–2910PubMed
4.
Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, JukkolaVuorinen A, Vuopala KS, Harris KW, Selander KS (2008) Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 6:1534–1543CrossRefPubMed
5.
Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108:4194–4197CrossRefPubMed
6.
Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117:3922–3929PubMed
7.
Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B (2008) CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 366:117–122CrossRefPubMed
8.
Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A (2008) Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57:987–996CrossRefPubMed
9.
McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin FH, Bowdish KS (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Nat Acad Sci USA 103:1041–1046CrossRefPubMed
10.
11.
Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768–1771CrossRefPubMed
12.
Kretz-Rommel A, Qin FH, Dakappagari N, Ravey EP, McWhirter J, Oltean D, Frederickson S, Maruyama T, Wild MA, Nolan MJ, Wu DY, Springhorn J, Bowdish KS (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178:5595–5605PubMed
13.
Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL (2007) Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 364:778–782CrossRefPubMed
14.
15.
Gorczynski RM, Chen Z, He W, Khatri I, Sun Y, Yu K, Boudakov I (2009) Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 183:1560–1568CrossRefPubMed
16.
Gorczynski RM, Cattral MS, Chen ZG, Hu JA, Lei J, Min WP, Yu G, Ni J (1999) An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 163:1654–1660PubMed
17.
Jakobsen CG, Rasmussen N, Laenkholm A-V, Ditzel HJ (2007) Phage display-derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78. Cancer Res 67:9507–9517CrossRefPubMed
18.
Andrews PD (2003) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005–5015CrossRef
19.
Wong K, Spaner DE, Gorczynski RM (2008) Lymphoma cell surface expression of CD200 modulates anti-tumor immunity (abstract). AAI, San Diego
20.
Wu L, Tannock IF (2003) Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 63:2134–2138PubMed
21.
Diao J, Smythe JA, Smyth C, Rowe PB, Alexander IE (1999) Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther 6:845–853CrossRefPubMed
22.
Blobel CP (2005) ADAMS: key players in EGFR-signaling, development and disease. Nat Rev Mol Cell Biol 6:32–43CrossRefPubMed
23.
Gorczynski RM, Chen Z, Hu J, Kai Y, Lei J (2001) Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin Exp Immunol 126:220–229CrossRefPubMed
24.
Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS (2008) Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 180:699–705PubMed
25.
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudo S, Ochiai A (2008) Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113:1387–1395CrossRefPubMed
26.
Gorczynski RM (2005) CD200 and its receptors as targets for immunoregulation. Curr Opin Invest Drugs 6:483–488
27.
Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267:204–215CrossRefPubMed
28.
Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M (2007) Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res 141:72–77CrossRefPubMed
29.
Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH (2007) Follicular lymphoma intratumoral CD4(+)CD25(+)GITR(+) regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8(+)CD25(-) and CD4(+)CD25(-) T cells. J Immunol 178:4051–4061PubMed
30.
Sakaguchi S (2004) Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562CrossRefPubMed
31.
Groux H (2003) Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 75:8S–12SCrossRefPubMed
32.
Jiang H, Chess L (2004) An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 114:1198–1208PubMed
33.
Kapp JA, Kapp LM, McKenna KC (2004) Gamma delta T cells play an essential role in several forms of tolerance. Immunol Res 29:93–102CrossRefPubMed
34.
Young KJ, Zhang L (2002) The nature and mechanisms of DN regulatory T-cell mediated suppression. Hum Immunol 63:926–934CrossRefPubMed
35.
Gorczynski RM, Chen Z, Kai Y, Wong S, Lee L (2004) Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 77:1138–1144CrossRefPubMed
36.
Gorczynski RM, Lee L, Boudakov I (2005) Augmented induction of CD4(+)CD25(+) Treg using monoclonal antibodies to CD200R. Transplantation 79:488–491CrossRefPubMed
37.
Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563CrossRefPubMed
38.
Cipriani B, Fridman A, Bendtsen C, Dharmapuri S, Mennuni C, Pak I, Mesiti G, Forni G, Monaci P, Bagchi A, Ciliberto G, LaMonica N, Scarselli E (2008) Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther 19:670–680CrossRefPubMed
39.
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59CrossRefPubMed
40.
Zhou JB, Zhang H, Gu PH, Bai JN, Margolick JB, Zhang Y (2008) NF-kappa B pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111:419–427CrossRefPubMed
41.
Liu ET (2008) Functional genomics of cancer. Curr Opin Genet Develop 18:251–256CrossRef
42.
Kuvaja P, Talvensaari-Mattila A, Turpeenniemi-Hujanen T (2008) High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma. Int J Cancer 123:846–851CrossRefPubMed
Metadata
Title
Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice
Authors
Reginald M. Gorczynski
Zhiqi Chen
Jun Diao
Ismat Khatri
Karrie Wong
Kai Yu
Julia Behnke
Publication date
01-09-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0667-8

Other articles of this Issue 2/2010

Breast Cancer Research and Treatment 2/2010 Go to the issue

Epidemiology

The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects

Epidemiology

MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls

Clinical trial

Corticosteroid treatment and timing of surgery in idiopathic granulomatous mastitis confusing with breast carcinoma

Preclinical study

A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action

Brief Report

Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival

Preclinical study

RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits